Alphatec director Keith Valentine buys $242,550 in company stock

Alphatec Holdings, Inc., a medical technology company, recently saw one of its directors, Keith Valentine, increase his ownership of the company. On November 10, 2026, Mr. Valentine purchased 35,000 shares of Alphatec common stock, amounting to a total value of $242,550. The acquisition occurred when the stock was trading near its 52-week low of $6.81, representing a 67% decrease year-to-date.

Financial analysis suggests that Alphatec is currently undervalued, ranking among the most undervalued stocks on InvestingPro's platform. The company has a market capitalization of $1.09 billion and has demonstrated a 15% year-over-year revenue growth. Following this transaction, Mr. Valentine now directly owns 299,283 shares of Alphatec Holdings common stock.

For further analysis of Alphatec's financial status and growth potential, InvestingPro provides access to in-depth Pro Research Reports on this and over 1,400 other US equities, along with additional ProTips. Meanwhile, Alphatec recently reported its third-quarter 2026 earnings, which fell short of Wall Street's expectations. The company reported adjusted earnings of $0.09 per share, less than the expected $0.10, and generated $221.17 million in revenue, missing the projected $225.44 million.

Although the company reported a 13% year-over-year revenue growth, the market responded negatively to declining biologics sales and a revised full-year outlook. Consequently, investment firms TD Cowen and Needham reduced their price targets for Alphatec, citing ongoing biologics-related challenges and a market slowdown. Despite these setbacks, both firms maintain a Buy rating on the company's shares.